祛风抗敏煎联合依巴斯汀治疗慢性荨麻疹临床观察

目的观察祛风抗敏煎联合依巴斯汀治疗慢性荨麻疹的临床疗效。方法 234例慢性荨麻疹患者随机分为治疗组118例和对照组116例。两组均给予依巴斯汀口服,1次10mg,1天1次。治疗组另加服祛风抗敏煎治疗。分别于治疗前及治疗2、4、6、8周和停药4周后评定疗效、复发率,观察治疗前后血清总Ig E水平、嗜酸性粒细胞计数变化。结果治疗组总有效率88.13%,对照组为80.17%,组间比较差异无统计学意义(P0.05)。治疗组、对照组治疗前后皮损评分比较(15.17±3.28比9.03±1.42、6.67±1.14、3.24±0.94、1.22±0.73、1.42±0.59和14.43±3.32比10.17、8.03±1.84、6.87±1.69、3.23±0.97、4.38±1.04),差异有统计学意义(P0.05或P0.01);治疗组治疗6、8周及停药4周皮损评分下降优于对照组(3.24±0.94比6.87±1.69,1.22±0.73比3.23±0.97,1.42±0.59比4.38±1.04,P均0.05)。治疗组、对照组治疗前后血清总Ig E水平比较(277.43±72.45比80.52±48.30,275.78±71.94比78.55±51.02),差异有统计学意义(P均0.05);两组治疗后血清总Ig E水平比较,差异无统计学意义(P0.05)。治疗组、对照组治疗前后血嗜酸性粒细胞计数比较(0.36±0.09比0.16±0.04,0.37±0.07比0.17±0.05),差异有统计学意义(P均0.05);治疗组治疗后血嗜酸性粒细胞计数明显低于对照组(0.16±0.04比0.17±0.05,P0.05)。停药4周后随访治疗组复发率为12.71%,低与对照组的35.35%,差异有统计学意义(P0.05)。结论祛风抗敏煎联合依巴斯汀治疗慢性荨麻疹疗效优于单纯西药治疗,且未见明显不良反应。

Clinical Observation of Patients with Chronic Urticaria under the Treatment of Combined Therapy of qufengkangminjian and Ebastine Tablets

Objective To observe the clinical effect of combined therapy of qufengkangminjian and Ebastine tablets (ET) on Chronic urticaria (CU). Methods 240 patients were randomly divided into the treatment group (120 patients) and the control group (120 patients), in which patients received the usual treatment of ET, and combined therapy of qufengkangminjian and ET individually for 8 weeks. Effect was respectively observed on 2th, 4th, 6th and 8th week. Relapse rates were recorded in 4 weeks after treatment. Serum total IgE and eosinophil count (EOS) were measured before and after treatment. Results Efficient rates of treatment group and control group were 88.13% and 80.17% respectively. There was not significantly statistical difference between two groups (P >0.05). But treatment group can drop the level of serum IgE and EOS. Relapse rates in two groups were 15.56% and 31.25% respectively. There was significantly statistical difference between two groups (P <0.05). Conclusion Combined therapy of qufengkangminjian and ET have high clinical efficacy and safety in treatment of CU .